From the work I have been doing globally now for over a decade, I am convinced that the organisations that sustain performance over the long term will increasingly be those willing to absorb higher short-term health costs in exchange for earlier intervention.
This appears counterintuitive within traditional HR and finance models. However, evidence from population health and actuarial analysis shows that proactive screening, diagnostics and early intervention increase near-term expenditure because clinicians identify previously undetected conditions earlier in their progression.
The alternative was not a healthier workforce, but one characterised by undiagnosed deterioration and latent risk.
This distinction matters. Late disease detection doesn’t avoid cost. It just defers and amplifies it.
Deloitte’s new longitudinal analysis of 59 million individuals demonstrates that sustained investment in early detection and prevention could reduce healthcare expenditure by up to $2.2 trillion annually in the US by 2040. This is equivalent to more than $7,000 per person and is precisely because earlier-stage intervention lowers downstream complexity and severity.
Prevention therefore represents cost acceleration in the short term, and cost avoidance over a longer horizon. Yet most organisations have not operationalised workforce health in this way, due to their natural short-termism.
A human depreciation curve
Over the past decade, businesses have developed increasingly sophisticated approaches to managing the depreciation of physical assets, modelling lifecycle value, scheduling maintenance and predicting replacement costs.
In contrast, organisations have left the gradual deterioration of human capability largely unmanaged.
Materiality doesn’t explain this imbalance. Across sectors, expenditure on people consistently exceeds expenditure on capital assets, even in capital-intensive industries such as manufacturing.
However, while organisations use structured interventions to mitigate and monitor asset depreciation, they rarely treat human deterioration with the same discipline.
We still frame workforce health as a discretionary spend rather than as a managed asset with measurable decline curves.
A more accurate model is a “human depreciation curve”. This is a progressive, often invisible erosion of physical, psychological and cognitive capacity driven by cumulative exposure to risk factors.
Without intervention, this deterioration is non-linear, accelerating as conditions transition from subclinical to chronic. The absence of measurement does not indicate absence of decline; it reflects a lack of system capability to detect it.
Prevention … represents cost acceleration in the short term, and cost avoidance over a longer horizon
Long-duration, preventable conditions drive workplace wellbeing
The underlying drivers of this curve have also shifted.
Across OECD economies the primary contributors to healthcare costs, workforce absence and economic inactivity are now chronic, non-communicable diseases. These include cardiovascular disease, diabetes, obesity, musculoskeletal disorders and mental ill health.
Modifiable risk factors strongly influence these conditions and they develop over extended time horizons.
The World Economic Forum has similarly identified workforce health as a determinant of economic resilience. Linking chronic disease prevalence directly to productivity and labour market participation.
This reframes workplace wellbeing from a support function to a systemic economic variable.
The central question is no longer whether organisations should engage in prevention. It’s how quickly they can identify physiological and psychological deterioration before it transitions into diagnosable disease.
The biological lag problem
However, a structural constraint persists.
Most organisations continue to evaluate prevention using accounting frameworks optimised for short-term efficiency, while the benefits of prevention accrue over longer periods.
Chronic diseases develop over decades, whereas business performance is typically assessed quarterly.
This creates a “biological lag” problem. This is the misalignment between the temporal dynamics of human health and the decision-making cycles of commercial organisations.
Within this lag, future health risk is frequently externalised or deferred – which is what most employers have been doing for the last 20 years.
The financial consequences of workforce ill health often emerge outside current planning horizons, weakening the immediate business case for investment.
As a result, interventions that would reduce long-term cost and preserve human capability are deprioritised in favour of initiatives with faster, more visible returns.
This logic would be considered irrational in other domains. Full financial returns within a single fiscal year aren’t expected from investments in cybersecurity, cloud infrastructure or data architecture.
They are classified as capability investments: essential to organisational resilience and future performance. It’s important to treat workforce health in the same way.
Chronic diseases develop over decades, whereas business performance is typically assessed quarterly
Reducing exposure to the conditions that make disease more likely
The economic case for this shift is strengthening. Preventative health interventions have been shown to generate measurable system-level impact within 10 to 15 years.
At the same time, the cost of workforce replacement, lost productivity and reduced participation continues to rise, reinforcing the value of retention and sustained capability.
Workplace wellbeing must transition from episodic support to continuous, preventative infrastructure.
This requires organisations to adopt longer-term measurement frameworks, capable of tracking the trajectory of workforce health over time, and to accept that early indicators of success may manifest as increased utilisation and rising short-term cost.
It also requires us to finally take a hard look at what we consider “workplace wellbeing” and what we invest in.
Inviting mental health speakers to do a talk, awareness days and mental health days start to become increasingly hard to defend in the light of this emerging research.
Those organisations that fail to adapt will continue to manage visible symptoms rather than underlying decline.
Those that do will build more stable, capable workforces, with lower long-term cost and higher sustained performance. The difference will be driven by time horizon, not intent.
Read another article by Gethin Nadin: UK employers have a design and delivery problem, not a generosity one
